Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec,

   Healthcare Sector Announced Financial Results and Recognition - Research
    Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA

PR Newswire

NEW YORK, November 15, 2013

NEW YORK, November 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Opko Health, Inc. (NYSE: OPK), Enzymotec
Ltd. (NASDAQ: ENZY), Cambrex Corporation (NYSE: CBM), and XOMA Corporation
(NASDAQ: XOMA). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Alnylam Pharmaceuticals, Inc. Research Report

On November 6, 2013,Alnylam Pharmaceuticals, Inc. (Alnylam) reported its
financial results for Q3 2013. The Company's revenue from research
collaborators decreased 46.4% YoY to $9million during the quarter. Net loss
was $29.7 million or $0.48 per diluted share in Q3 2013, compared to net loss
of $19.5 million or $0.38 per diluted sharein Q3 2012. Commenting on the
results,John Maraganore, Ph.D.,CEO of Alnylam, said, "This was a quarter of
remarkable progress at Alnylam. A key highlight was achievement of positive
data from our Phase I clinical trial with ALN-TTRsc in development for the
treatment of familial amyloidotic cardiomyopathy. In this study, we
demonstrated knockdown of serum TTR of up to 94% and showed that ALN-TTRsc was
generally safe and well tolerated, thereby confirming human translation of our
proprietary GalNAc-siRNA conjugate delivery platform. As such, we believe
these data are very important not only for our ALN-TTRsc program, but for the
entirety of our 'Alnylam 5x15' pipeline which employs this now clinically
validated delivery approach." The Full Research Report on Alnylam
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

Opko Health, Inc. Research Report

On November 11, 2013, Opko Health, Inc. (Opko) reported its financial and
operational highlights for Q3 2013. The Company's revenue was $20.6 million
during the quarter, compared to $11.8 million in Q3 2012. Net loss was $60.0
million in Q3 2013, compared to a net loss of $10.2 million in Q3 2012.
Additionally, the Company informed about its initiation of a multi-center
study on November 4, 2013, which is expected to generate data to support the
launch of the 4Kscore™ test as a laboratory developed test through its
Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratory
in Nashville, Tennessee. The Full Research Report on Opko Health, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cd43_OPK

Enzymotec Ltd. Research Report

On November 11, 2013, Enzymotec Ltd. (Enzymotec) reported its financial
results for Q3 2013. Net revenue increased 66.3% YoY to $17.8 million during
the quarter. Net income was $3.3 million or $0.13per diluted share in Q3 2013,
compared to net income of $1.7million or $0.10 per diluted share in Q3 2012.
Commenting on the results, President and CEOof Enzymotec, Dr. Ariel Katz said,
"We are pleased to report a very strong quarter, highlighted by record sales,
cash flow and profitability. Our top line performance was driven by robust
performance in both our Nutrition and VAYA Pharma segments, which grew 68.9%
and 159.7% year-over-year, respectively." The Full Research Report on
Enzymotec Ltd. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f522_ENZY

Cambrex Corporation Research Report

On November 5, 2013, Cambrex Corporation (Cambrex) announced that the
Company's name featured in an article, titled "Nice-Sized - A Pharmaceutical
Manufacturer Says It Has What It Takes to Serve Clients Both Large And Small"
in the magazine, Manufacturing Today's fall 2013 issue. According to the
article, the Company's sales reached $277.9 million in 2012 and it anticipates
the same to grow in the range of 8%-12% in 2013, strengthening its position in
the industry. Simon Edwards, VP of Global Sales and Business Development at
Cambrex, said, "It's a mid-sized company with a really good balance. It's
almost a unique balance because we have custom manufacturing, generic API and
formulated drug product capabilities. We are not a big behemoth and are small
enough to be customer focused." The Full Research Report on Cambrex
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1169_CBM

XOMA Corporation Research Report

On November 7, 2013,XOMA Corporation (XOMA) reported its financial results for
Q3 2013. Revenue fell 12.9% YoY to $6.3 million during the quarter. XOMA had a
net loss of $29.6 million or $0.34 per diluted share in Q3 2013, compared with
a net loss of $26.9 million or $0.39 per diluted share inQ3 2012. Commenting
on the results, CEO of XOMA, John Varian said, "By the end of October, we
received the initial data from all four pyodermagangrenosum patients enrolled
in our pilot study, as well as data from two patients with generalized
pustular psoriasis who received gevokizumab under a compassionate use
protocol. These two rare indications fall under the neutrophilicdermatoses
umbrella, which are a group of conditions that are characterized by skin
lesions that have intense epidermal and/or dermal inflammatory infiltrates,
yet show no sign of infection. While we have treated only a very small number
of patients, the apparent responses are compelling." The Full Research Report
on XOMA Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9a56_XOMA

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)